Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Sell at StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was upgraded by StockNews.com to a “sell” rating in a report issued on Monday.

Pulse Biosciences Price Performance

NASDAQ:PLSE traded down $0.51 during mid-day trading on Monday, reaching $16.09. The company’s stock had a trading volume of 459,987 shares, compared to its average volume of 198,258. The firm’s fifty day moving average price is $18.78 and its two-hundred day moving average price is $18.15. Pulse Biosciences has a 12-month low of $6.60 and a 12-month high of $25.00.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in PLSE. Tower Research Capital LLC TRC raised its stake in Pulse Biosciences by 98.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company’s stock valued at $29,000 after buying an additional 838 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Pulse Biosciences by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company’s stock worth $2,598,000 after acquiring an additional 1,092 shares during the period. Farther Finance Advisors LLC increased its position in Pulse Biosciences by 44.4% during the fourth quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company’s stock valued at $126,000 after acquiring an additional 2,220 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Pulse Biosciences by 27.1% in the fourth quarter. Wells Fargo & Company MN now owns 11,315 shares of the company’s stock valued at $197,000 after acquiring an additional 2,416 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in Pulse Biosciences in the fourth quarter worth about $44,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.